Press release

Péter Ferdinandy, MD, PhD, MBA, Founder & CEO of Pharmahungary Group has been noticed as ‘Highly Cited Researcher’ for the 5th time and elected as Editor-in-Chief of British Journal of Pharmacology

Budapest, Hungary, 30 November 2022 – Péter Ferdinandy, MD, PhD, MBA, Founder & CEO of Pharmahungary Group, Head of Department of Pharmacology and Pharmacotherapy and Vice-Rector for Science and Innovations of Semmelweis University, Budapest, Hungary has received two scientific recognitions recently. Prof. Ferdinandy has been noticed as a ‘Highly Cited Researcher’ by Clarivative and has been elected as Editor-in-Chief of British Journal of Pharmacology.

The long waited ‘Highly Cited Researchers’ list for 2022 has been released by Clarivative. Less than 7,000, or about 0.1%, of the world’s researchers has been noticed as Highly Cited Researchers this year in 21 research fields. The exceptional research influence of these researchers is demonstrated by the production of multiple highly cited papers that rank in the top 1% by citations for field and year in the Web of Science™. Prof. Ferdinandy has been noticed for the 5th time as ‘Highly Cited Researcher’ after 2014, 2017, 2020, and 2021.

Prof. Ferdinandy will also serve as Editor-in-Chief from January 1st, 2023 of BJP, one of the most prestigious journals in pharmacology with an impact factor of 9,5. Professor Ferdinandy said that during his time as Editor-in-Chief his main aim is to “drive science and innovations in all areas of pharmacology in the 21st century„.

Prof. Ferdinandy is considered one of the worldwide key opinion leaders in pharmacology of cardioprotection. Besides being the CEO of a successful group of R&D companies he is also the Vice-Rector for Science and Innovations and Professor and Director of the Department of Pharmacology and Pharmacotherapy at Semmelweis University, Budapest, Hungary as well as the President of the Hungarian Society of Pharmacology and Executive Committee member of the European Federation of Pharmacological Societies.

About Pharmahungary Group
Pharmahungary Group is an ISO 9001:2015 certified Hungarian SME developing innovative in-house R&D projects for valorization and providing preclinical and clinical R&D services since 2003.
• Preclinical R&D services: from in vitro to in vivo studies including custom designed, co-morbidity, and large animal models, e.g. Göttingen minipigs, focusing on but not limited to cardiovascular, metabolic, and renal disease models.
• Clinical R&D services: full management of clinical trials with Medical Devices including In Vitro Diagnostics, ATMPs, Investigator Initiated Trials, and niche trials that need strong scientific and regulatory consulting, e.g. clinical trials on sensitive patient population